These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18305914)

  • 1. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].
    Ringe JD; Nitschmann S
    Internist (Berl); 2008 Apr; 49(4):502-4. PubMed ID: 18305914
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
    Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
    J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
    N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual zoledronic acid for osteoporosis.
    BMJ Group
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Zoledronic acid reduces risk of any new clinical fracture and risk of death after surgical repair of a low-trauma hip fracture].
    Leszczyński P
    Chir Narzadow Ruchu Ortop Pol; 2010; 75(3):168-71. PubMed ID: 21038635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid: a review of its use in the treatment of osteoporosis.
    Deeks ED; Perry CM
    Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
    Dalle Carbonare L; Bertoldo F; Lo Cascio V
    Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of zoledronic acid therapy on postmenopausal osteoporosis between the Uighur and Han population in Xinjiang: An open-label, long-term safety and efficacy study.
    Xu W; Xiang C; Wang H; Yuan H; Zhao X; Xiao X
    J Clin Pharm Ther; 2018 Jun; 43(3):336-341. PubMed ID: 29114907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
    Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
    Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yearly zoledronic acid in postmenopausal osteoporosis.
    Chang JT
    N Engl J Med; 2007 Aug; 357(7):713-4; author reply 714-5. PubMed ID: 17703528
    [No Abstract]   [Full Text] [Related]  

  • 13. A once-yearly IV bisphosphonate for osteoporosis.
    Obstet Gynecol; 2008 May; 111(5):1208-9. PubMed ID: 18448761
    [No Abstract]   [Full Text] [Related]  

  • 14. Zoledronic acid--once-yearly. Corticosteroid-induced osteoporosis: no benefit.
    Prescrire Int; 2010 Apr; 19(106):63. PubMed ID: 20568485
    [No Abstract]   [Full Text] [Related]  

  • 15. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract]   [Full Text] [Related]  

  • 16. [Once-yearly administration of zoledronic acid to treat post-menopausal osteoporosis].
    Seitz S; Schieker M; Mutschler W
    Unfallchirurg; 2009 Mar; 112(3):346-8. PubMed ID: 19240992
    [No Abstract]   [Full Text] [Related]  

  • 17. Association between timing of zoledronic acid infusion and hip fracture healing.
    Colón-Emeric C; Nordsletten L; Olson S; Major N; Boonen S; Haentjens P; Mesenbrink P; Magaziner J; Adachi J; Lyles KW; Hyldstrup L; Bucci-Rechtweg C; Recknor C;
    Osteoporos Int; 2011 Aug; 22(8):2329-36. PubMed ID: 21153021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.
    Hamdy RC
    Drug Des Devel Ther; 2010 Nov; 4():321-35. PubMed ID: 21151620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis.
    Taggart H; Cheng J; Archbold P
    Osteoporos Int; 2010 Sep; 21(9):1621-2. PubMed ID: 19813042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.